Oscient Pharmaceuticals Corp. (OSCI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oscient Pharmaceuticals Corp. (OSCI)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Ian@SI	10/11/2006 1:48:22 PM
	Read Replies (1) of 1154

Looks like PFE selling Factive in Mexico hasn't been much help... Oscient Estimates 3Q Rev Growth On Antara Rights Purchase DOW JONES NEWSWIRES October 11, 2006 8:58 a.m. DOW JONES NEWSWIRES Oscient Pharmaceuticals Corp. (OSCI) expects to report that third-quarter revenue climbed to slightly more than $11 million from $5.94 million a year ago, helped by the August acquisition of the U.S. rights to cardiovascular drug Antara. The Waltham, Mass., company said Wednesday it expects to generate third-quarter revenue of about $4 million from Antara 130-milligram capsules. The biopharmaceutical concern anticipates its revenue from Factive tablets, a treatment for respiratory tract infections, will decrease to about $4 million from $4.8 million a year earlier. Oscient plans to report quarterly financial results on Nov. 9.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next